Evidence map›Paper›PMID 22790221›Full record

ArticleChromosoma2012

A TRF1-controlled common fragile site containing interstitial telomeric sequences.

Nazario Bosco, Titia de Lange

Abstract read
In one paragraph

Article in Chromosoma, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Telomeric small RNAs in the genusRNA (New York, N.Y.) · 2019
    Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. The methylation and telomere landscape in two families of marsupials with different rates of chromosome evolution.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2018
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nazario BoscoLaboratory for Cell Biology and Genetics, The Rockefeller University, Box 159, 1230 York Avenue, New York, NY 10065, USA.
Titia de Lange
Rockefeller University · US

Funding

MECHANISMS OF TELOMERE INDUCED SENESCENCER01AG016642 · NIA · ROCKEFELLER UNIVERSITY · PI Titia de Lange · 1999 to 2026
$11.9M
Mechanism of the telomeric proliferation limitR56AG016642 · NIA · ROCKEFELLER UNIVERSITY · PI DE LANGE, TITIA · 2019 to 2019
$598k
NIA NIH HHS AG16642NIA NIH HHS R01 AG016642NIA NIH HHS R56 AG016642
6 · The paper itself

Abstract

Mouse telomeres have been suggested to resemble common fragile sites (CFS), showing disrupted TTAGGG fluorescent in situ hybridization signals after aphidicolin treatment. This "fragile" telomere phenotype is induced by deletion of TRF1, a shelterin protein that binds telomeric DNA and promotes efficient replication of the telomeric ds[TTAGGG]n tracts. Here we show that the chromosome-internal TTAGGG repeats present at human chromosome 2q14 form an aphidicolin-induced CFS. TRF1 binds to and stabilizes CFS 2q14 but does not affect other CFS, establishing 2q14 as the first CFS controlled by a sequence-specific DNA binding protein. The data show that telomeric DNA is inherently fragile regardless of its genomic position and imply that CFS can be caused by a specific DNA sequence.

Indexed as

Chromosome Fragile SitesAnimalsBase SequenceCell Line, TumorChromosomal InstabilityChromosomes, Human, Pair 2HumansMiceMolecular Sequence DataProtein BindingTelomereTelomeric Repeat Binding Protein 1Telomeric Repeat Binding Protein 1

Identifiers

PMID22790221
PMCPMC3590843
OpenAlexW2110926898

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.